Evidence map›Paper›PMID 41212313›Full record

ArticleWorld journal of urology2025

In vitro ablation rates of Ho:YAG, p-Tm:YAG and TFL lasers.

A Quarà, A Bravo-Balado, S Moretto, A Madden, F Zorzi, L M I Jannello, S Kutchukian, J Cabrera, M Corrales, M Chicaud and 9 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

A QuaràGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France. quara.alberto@gmail.com.
A Bravo-BaladoGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
S MorettoGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
A MaddenGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
F ZorziGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
L M I JannelloGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
S KutchukianGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
J CabreraGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
M CorralesGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
M ChicaudGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
U GradiloneGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
L CandelaGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
C GornyPIMM, UMR 8006 CNRS-Arts et Métiers ParisTech, 151 bd de l'Hôpital, Paris, 75013, France.
F CostePIMM, UMR 8006 CNRS-Arts et Métiers ParisTech, 151 bd de l'Hôpital, Paris, 75013, France.
L BerthePIMM, UMR 8006 CNRS-Arts et Métiers ParisTech, 151 bd de l'Hôpital, Paris, 75013, France.
S DoiziGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
F PanthierGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.
C FioriDivision of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
O TraxerGRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Sorbonne Université, Paris, 75020, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study compares the ablation rates of three laser systems—Holmium:YAG (Ho:YAG), Thulium Fiber Laser (TFL), and Pulsed Thulium:YAG (p-Tm:YAG)—for renal stone lithotripsy using a standardized robotic setup. MATERIALS AND

methodsA robotic arm enabled consistent laser application on stone phantoms simulating calcium oxalate monohydrate (hard) and uric acid (soft) stones. Ablation efficiency (mm³/J) was assessed across different laser settings (0.2 J–50 Hz, 0.5 J–20 Hz, and 1.0 J–10 Hz) and fiber diameters (200 and 272 μm). Ablated volumes were quantified via micro-CT and 3D segmentation using 3DSlicer. Statistical analysis evaluated differences in performance.

resultsTFL demonstrated the highest ablation rates for both hard and soft stones, significantly outperforming Ho:YAG in multiple settings. For hard stones, TFL exhibited greater ablation efficiency than Ho:YAG, particularly at 0.5 J–20 Hz and 1.0 J–10 Hz. The p-Tm:YAG laser also outperformed Ho:YAG at 0.5 J–20 Hz. For soft stones, the difference between TFL and Tm:YAG was statistically significant at lower energy settings (0.20 J–50 Hz and 0.5 J–20 Hz). Compared to Ho:YAG, TFL showed significantly higher ablation rates across all tested settings (p < 0.05). The p-Tm:YAG laser showed intermediate performance, with higher efficiency than Ho:YAG but slightly lower than TFL. Fiber diameter influenced ablation, with 272 μm fibers yielding greater efficiency at lower energy settings (p < 0.05 at 0.20 J − 50 Hz and 0.5 J − 20 Hz for both stone types); this comparison was limited to p-Tm:YAG, as data for the other lasers are already available in the literature.

conclusionTFL achieved the highest in vitro ablation efficiency. However, p-Tm:YAG represents a promising compromise, offering improved performance over Ho:YAG and a balanced profile between fragmentation and dusting capabilities.

Indexed as

Kidney CalculiLasers, Solid-StateLithotripsy, LaserThuliumCalcium OxalateHumansIn Vitro TechniquesCalcium OxalateThuliumAblationHo:YAGKidney stonesLaser lithotripsyPulsed Thulium:YAG laserThulium fiber laser

Identifiers

PMID41212313
PMCPMC12602604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.